SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	ROVAL				
OMB Number:	3235-0287				
Estimated average burden					
hours per response:	0.5				

	tion 1(b).	ue. 366		File							es Exchanç npany Act c		934		nours	per res	ponse:	0.5
1 I. Name and Address of Reporting Feison					2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ZIOP]							(Cł	neck all applie X Directo	cable) or	,			
	(F IRD SECUI ROVE AVE	RITY, LLC	10/0				3. Date of Earliest Transaction (Month/Day/Year) 10/05/2018							Officer below)	(give title		Other (s below)	specify
(Street) RADFO	RD V.	A	24141		4. If							Lin	6. Individual or Joint/Group Filing (Che Line) Form filed by One Reporting X Form filed by More than One Person			, rting Perso	n	
(City)	(S		(Zip)	Doriv		. 50	ouri	tion An	nuirod	Die		f or Po		ly Owned	1			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Date)			action	ction 2A. Deemed Execution Date,			Code (Instr. 5)				d (A) or	5. Amou Securitie Beneficia Owned F	nt of es ally Following	Form: Direct (D) or Indire		Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)
			Table II -								osed of, onvertik			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	d 4. Date, Ti	ransac	ction	5. Number of Derivative		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio	G Ownersh Form: Ily Direct (D or Indirect (I) (Instr.	Ownership	Beneficial Ownership (Instr. 4)
				c	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Series 1 Preferred Stock	(1)	10/05/2018			J			130,849	(1)		(1)	Common Stock	(1)	(1)	0		Ι	by Intrexon ⁽²⁾
	nd Address of RANDAI	Reporting Person [*]																
	IRD SECUI ROVE AVE		(Midd	le)														
(Street)																		

1. Name and Address o	f Reporting Person [*]							
INTREXON CO	<u>DRP</u>							
(Last)	(First)	(Middle)						
C/O LEGAL DEPARTMENT								
20374 SENECA M	EADOWS PARKWA	Y						
(Street)								
GERMANTOWN	MD	20876						
(City)	(State)	(Zip)						

(Zip)

(State)

Explanation of Responses:

(City)

1. On October 5, 2018, the issuer and Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation ("Intrexon"), entered into a definitive license agreement to replace all existing agreements between the companies. In partial consideration for the termination of the former agreements, the companies agreed that the issuer would retire all outstanding shares of its Series 1 Preferred Stock held by Intrexon, including any accrued dividends, as of September 30, 2018.

2. Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

<u>/s/ Randal J. Kirk</u>	<u>10/09/2018</u>
/s/ Randal J. Kirk. CEO of	10/09/2018

Intrexon Corporation

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.